Last week, Novartis was proud to share positive data from the Phase III KALUMA trial for a next-generation antimalarial candidate. Discovered in our San Diego Biomedical Research labs and developed with the help of our partners, this innovative therapy has the potential to not only treat malaria but also play a critical public health role by helping to prevent transmission and address the rising threat of drug-resistant parasites. This milestone is the product of years of relentless scientific pursuit, internal and external collaboration, and a shared determination to reimagine what’s possible in global health. Novartis remains committed to going first and further to advance innovations so that, together with our partners, we can create a world free from malaria. #drugdevelopment #malaria #globalhealth Medicines for Malaria Venture | European & Developing Countries Clinical Trials Partnership (EDCTP) | WANECAM
About us
Novartis is an innovative medicines company with research and development at its core. Our R&D engine powers an industry-leading pipeline dedicated to delivering transformative medicines to fight disease, restore possibilities and help people live life on their own terms. See our community guidelines: https://go.novartis.social/4bqbjuA
- Website
-
https://www.novartis.com/research-development
External link for Novartis Science
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Cambridge, MA
Updates
-
Novartis Science reposted this
Today at American College of Rheumatology ACR Convergence 2025, we presented the results of the first ever global, Phase III trials to demonstrate a statistically significant reduction in disease activity in Sjögren’s disease. While Sjögren’s is the second most common rheumatic condition after rheumatoid arthritis, there are no approved systemic therapies for patients. Our data marks a turning point in the understanding of this disease and ability to potentially treat it. These results are the first data of our investigational asset, which we are studying in multiple indications across a range of B-cell driven autoimmune diseases with high unmet needs. I am encouraged by these results, and the increase in dialogue and attention on Sjögren’s. People living with this disease have often been unrecognized or misdiagnosed, which has seriously impacted their quality of life. Thank you to all Novartis teams for staying at the forefront of scientific progress and bringing hope to this community. Read more about our announcement here: https://lnkd.in/duSf6JpB #ACR25
-
Novartis Science reposted this
I’m proud of the transformative data our Novartis teams are sharing at #ESMO25 across advanced prostate cancer and early breast cancer. Today, we’re presenting new Phase III data showing that, in metastatic hormone-sensitive prostate cancer, combining our radioligand therapy with standard of care slowed disease progression. These results mark our third positive Phase III study for this treatment. If approved for earlier use, our treatment would be available to about twice as many patients and become a treatment option across all stages of metastatic prostate cancer - one of the most common cancers in men. Bringing new and effective options into earlier stages can make a meaningful difference for patients and their families. Our teams also presented data that continues to evolve clinical practice and standard of care for patients living with breast cancer. New five-year data shows our CDK4/6 inhibitor continues to reduce the risk of recurrence in the broadest early breast cancer population. The majority of patients diagnosed with breast cancer are treated early, but live with the persistent risk and worry of recurrence despite curative intent from initial treatment. We continue to build on our track record of firsts in oncology, meaningfully advancing care and redefining what’s possible. Learn more about our data at ESMO in our press releases here https://lnkd.in/dmffHRss and here https://lnkd.in/dasYEe6M.
-
We are excited to announce that Dr. Philippe Schwaller, Assistant Professor and leader of the Laboratory of Artificial Chemical Intelligence (LIAC), EPFL, Lausanne, Switzerland, has received the 2025 Novartis Early Career Award (NECA). This prestigious honor recognizes a scientist within the first several years of starting an independent career in chemistry, offering two years of funding and an invitation to present at the Novartis campus in Basel or Cambridge. Prof. Schwaller is widely recognized for his pioneering work at the interface of artificial intelligence and chemistry, with particular emphasis on AI-driven molecular discovery and synthesis. His research integrates advanced machine learning methodologies to enhance drug development processes, offer accessible AI solutions for chemists, and provide automated, reliable systems for reaction prediction and classification, all with an emphasis on sustainability. Notably, Prof. Schwaller has developed a model-based approach that enables efficient exploration of virtual chemical space, targeting areas with significant molecular potential. Collaboration has been central to his approach, enabling interdisciplinary partnerships that further advance the application of AI in chemistry. We applaud Prof. Schwaller’s many impactful contributions to the field and congratulate him for this well-earned distinction.
-
-
Novartis researchers publish hundreds of papers each year in scientific journals, to contribute to the collective knowledge of the scientific community as we seek to improve human health, together. Please enjoy this selection of recent papers published by our researchers and collaborators from across academia and industry. From new insights on disease risk and progression, to discoveries that could pave the way for future drug development, these papers highlight the fruits of some of the bold science happening across Novartis R&D. #scientificpublications #biomedicine
-
Launched in 1998, the VIVA (Vision, Innovation, Value, and Achievement) Awards recognize exceptional contributions made by Novartis scientists and clinicians across R&D. The program aspires to foster research, technical, and clinical excellence towards the realization of our goal to reimagine medicine to improve and extend people's lives. Since its inception, more than 400 people have been recognized with VIVA Awards for scientific contributions that have made an indelible impact at Novartis and for patients around the world. Last week, we celebrated this year’s awardees at a ceremony in Basel, joined by families, Novartis colleagues, our CEO Vas Narasimhan, our President of Biomedical Research Fiona H. Marshall, and our President of Development and Chief Medical Officer Shreeram Aradhye. Congratulations to all our 2025 VIVA Awardees!
-
For decades, Novartis has been committed to bringing the best science to some of the biggest global health challenges. That investment in innovation has produced a pipeline of approved and potential medicines that is reimagining what’s possible for people who are susceptible to neglected tropical diseases, which represent an enormous health burden worldwide. In recent years, we have doubled down on that commitment, with scientific discoveries leading to the ongoing development of more potential malaria therapies, as well as investigational approaches to treating leishmaniosis, dengue fever, cryptosporidiosis, and Chagas disease. We’re proud to be advancing breakthrough innovations that could redefine the future of care for millions at risk from these long-neglected global health threats and are honored to be recognized for social impact by Fierce 50 Life Sciences. Thank you and congratulations to the researchers, clinicians, patients, and partners who have contributed to this important work over the years. Read the article to learn more about our commitment to global health from Novartis President of Global Health Dr. Lutz Hegemann: https://lnkd.in/gKyFDA3P #globalhealth #malaria
-
-
Novartis Science reposted this
Systemic inflammation is a key driver of cardiovascular risk, yet no widely adopted anti-inflammatory therapies currently address this critical unmet need in atherosclerotic cardiovascular disease (ASCVD). That’s why today’s announcement of Novartis’ agreement to acquire Tourmaline Bio is particularly exciting. Tourmaline is developing a promising targeted therapy for ASCVD that aims to reduce cardiovascular inflammation, and we are excited to collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care. For more information and cautionary statements: https://lnkd.in/dhWW7S4g #Novartis #CardiovascularHealth #Innovation #HeartCare #CVD
-
Over the last quarter century, Novartis researchers at our California sites have driven biomedical breakthroughs that have reached patients around the globe. In this Q&A, Thierry Diagana, California Sites Head for Novartis Biomedical Research, speaks about our vision for a new, state-of-the-art research facility in San Diego that will further drive innovation and fuel the next wave of transformative research. https://lnkd.in/gCGpttnY #drugdiscovery #SanDiegoBiotech
-
-
Novartis first established its presence in San Diego in 1999 with the founding of a center dedicated to accelerating drug discovery through a greater understanding of genomic science—before the first human genome had even been fully sequenced. Since then, our San Diego site has been the home of cutting-edge mechanistic research in numerous disease areas, pioneering work in target discovery and structural genomics, as well as groundbreaking technological development that has enabled high-throughput biology studies across Novartis and the global research community. As we embark on the creation of a new, state-of-the-art Biomedical Research Hub in San Diego, we’re taking a look back at our 25+ year legacy of R&D innovation in this vibrant life sciences ecosystem. Read the story here. https://lnkd.in/gtvmdNAi #biomedicalresearch #biotech